Trial Profile
A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder
Status:
Discontinued
Phase of Trial:
Phase III/IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 23 Dec 2020 Number of treatment arms has been increased from 2 to 4 and treatments section is modified to include 3 double-blind phase arms of Aripiprazole-full dose, half dose and placebo, and an open label stabilization phase arm of Aripiprazole.
- 10 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 11 Jun 2020 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.